Exp Mol Med.  2016 Sep;48(9):e257. 10.1038/emm.2016.78.

Osteoactivin inhibition of osteoclastogenesis is mediated through CD44-ERK signaling

Affiliations
  • 1Department of Anatomy and Neurobiology, Northeast Ohio Medical University (NEOMED), College of Medicine, Rootstown, OH, USA. fayez.safadi@neomed.edu
  • 2School of Biomedical Sciences, Kent State University, Kent, OH, USA.
  • 3Department of Pharmaceutical Sciences, Northeast Ohio Medical University (NEOMED), College of Pharmacy, Rootstown, OH, USA.
  • 4Department of Biological Sciences, Kent State University, Kent, OH, USA.
  • 5Department of Biology, King Abdulaziz University, Jeddah, KSA.
  • 6Department of Pharmaceutical Sciences, West Virginia University, Morgantown, WV, USA.
  • 7Department of Orthopedics, Summa Health Systems, Akron, OH, USA.

Abstract

Osteoactivin is a heavily glycosylated protein shown to have a role in bone remodeling. Previous studies from our lab have shown that mutation in Osteoactivin enhances osteoclast differentiation but inhibits their function. To date, a classical receptor and a signaling pathway for Osteoactivin-mediated osteoclast inhibition has not yet been characterized. In this study, we examined the role of Osteoactivin treatment on osteoclastogenesis using bone marrow-derived osteoclast progenitor cells and identify a signaling pathway relating to Osteoactivin function. We reveal that recombinant Osteoactivin treatment inhibited osteoclast differentiation in a dose-dependent manner shown by qPCR, TRAP staining, activity and count. Using several approaches, we show that Osteoactivin binds CD44 in osteoclasts. Furthermore, recombinant Osteoactivin treatment inhibited ERK phosphorylation in a CD44-dependent manner. Finally, we examined the role of Osteoactivin on receptor activator of nuclear factor-κ B ligand (RANKL)-induced osteolysis in vivo. Our data indicate that recombinant Osteoactivin inhibits RANKL-induced osteolysis in vivo and this effect is CD44-dependent. Overall, our data indicate that Osteoactivin is a negative regulator of osteoclastogenesis in vitro and in vivo and that this process is regulated through CD44 and ERK activation.


MeSH Terms

Bone Remodeling
In Vitro Techniques
Osteoclasts
Osteolysis
Phosphorylation
Stem Cells
Full Text Links
  • EMM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr